Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age

Vaccine

Volumn 32, Issue 45, 2014, Pages 5931-5936

  Aase, Audun ^a   Herstad, Tove Karin ^a   Jørgensen, Silje Bakken ^b   Leegaard, Truls Michael ^b   Berbers, Guy ^c   Steinbakk, Martin ^a   Aaberge, Ingeborg ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS ANTIBODY; PERTUSSIS TOXIN; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; ADHESIN; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; DTPP VACCINE; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; IMMUNOGLOBULIN G; VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; PERTUSSIS; POLIOMYELITIS; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION; BLOOD; IMMUNIZATION; IMMUNOLOGY; NORWAY; WHOOPING COUGH;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; CHILD; CROSS-SECTIONAL STUDIES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; NORWAY; PERTUSSIS TOXIN; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 84907983340     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.069     Document Type: Article

References (28)

1. Chiappini E., Stival A., Galli L., de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013, 13:151.
2. Poland G.A. Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations. Vaccine 2012, 30:6957-6959.
3. Vickers D., Ross A.G., Mainar-Jaime R.C., Neudorf C., Shah S. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. Can Med Assoc J 2006, 175:1213-1217.
4. Bentsi-Enchill A.D., Halperin S.A., Scott J., MacIsaac K., Duclos P. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997, 15:301-306.
5. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-356.
6. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
7. Sheridan SIW R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. J Am Med Assoc 2012, 308:454-456.
8. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis: Off Publ Infect Dis Soc Am 2013, 56:1248-1254.
9. Hallander H.O., Gustafsson L., Ljungman M., Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa: response to a first booster dose-years after the third vaccine dose. Vaccine 2005, 23:5359-5364.
10. Dalby T., Petersen J.W., Harboe Z.B., Krogfelt K.A. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol 2010, 59:1029-1036.
11. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., Wassilak S.G.F. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatrics 1998, 132:983-988.
12. McIntyre P.B., Burgess M.A., Egan A., Schuerman L., Hoet B. Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 2009, 27:1062-1066.
13. de Melker H.E., Versteegh F.G., Conyn-Van Spaendonck M.A., Elvers L.H., Berbers G.A., van Der Zee A., et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000, 38:800-806.
14. Guiso N., Berbers G., Fry N.K., He Q., Riffelmann M., Wirsing von König C.H. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011, 30:307-312.
15. Hallander H.O., Ljungman M., Storsaeter J., Gustafsson L. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. Acta Pathol, Microbiol, Immunol Scand 2009, 117:797-807.
16. Dalby T., Seier-Petersen M., Kristiansen M.P., Harboe Z.B., Krogfelt K.A. Problem solved: a modified enzyme-linked immunosorbent assay for detection of human antibodies to pertussis toxin eliminates false-positive results occurring at analysis of heat-treated sera. Diagn Microbiol Infect Dis 2009, 63:354-360.
17. Aase A., Herstad T.K., Merino S., Bolstad M., Sandbu S., Bakke H., et al. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity. Clin Vaccine Immunol 2011, 18:1269-1274.
18. Hallander H.O., Andersson M., Gustafsson L., Ljungman M., Netterlid E.V.A. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. Acta Pathol, Microbiol, Immunol Scand 2009, 117:912-922.
19. Schure R.-M., Hendrikx L.H., de Rond L.G.H., Öztürk K., Sanders E.A.M., Berbers G.A.M., et al. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination. Clin Vaccine Immunol 2013, 20:1388-1395.
20. Plotkin S.A. Complex correlates of protection after vaccination. Clin Infect Dis 2013, 56:1458-1465.
21. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16:1907-1916.
22. Klein N., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019.
23. van der Maas N.A., Mooi F.R., de Greeff S.C., Berbers G.A., Spaendonck M.A., de Melker H.E. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants?. Vaccine 2013, 31:8.
24. Mattoo S., Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005, 18:326-382.
25. Le T., Cherry J.D., Chang S-J., Knoll M.D., Lee M.L., Barenkamp S., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis 2004, 190:535-544.
26. Hendrikx L.H., Berbers G.A.M., Veenhoven R.H., Sanders E.A.M., Buisman A-M. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 2009, 27:6530-6536.
27. Hegerle N., Paris A.S., Brun D., Dore G., Njamkepo E., Guillot S., et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect 2012, 18:E340-E346.
28. Pawloski L.C., Queenan A.M., Cassiday P.K., Lynch A.S., Harrison M., Shang W., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol 2014, 21(2):119.